Adaptimmune Therapeutics Plc - ADR
NASDAQ:ADAP
| Market Cap (Intraday) | 16.46M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.05 |
| 50-Day MA | $0.14 |
| 200-Day MA | $0.36 |
Adaptimmune Therapeutics Plc - ADR Stock, NASDAQ:ADAP
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX
United Kingdom
Phone: +44.1235.430000
Number of Employees: 449
Description
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.